Clinical trial · Observational
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia
NCT07413263CI-TRIAL-00103584not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Tyrosine kinase Inhibitors (Imatinib & Nilotinib) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- timeFrame
- Baseline and 3, 6, 9, and 12 months
- description
- Assessment of change in HbA1c levels in CML patients treated with TKIs.
Secondary outcomes (1)
- measure
- Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
- timeFrame
- Baseline and 3, 6, 9, and 12 months
- description
- Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * CML patients free medical history Exclusion Criteria: * diabetic
References
Publications (1)
- BACKGROUNDHwang SM, Im SH, Rudra D. Signaling networks controlling ID and E protein activity in T cell differentiation and function. Front Immunol. 2022 Aug 2;13:964581. doi: 10.3389/fimmu.2022.964581. eCollection 2022. PMID 35983065